Exton, United States
Melior Discovery is a biopharmaceutical and biotechnology company headquartered in the United States. Founded in 2005, the company's mission is to "Capture the Untapped Value of Therapeutics". Melior Discovery Inc has developed a groundbreaking "high throughput" in vivo pharmacology platform known as theraTRACE®, which enables the systematic identification of novel indications for pre-clinical and development stage drugs. This platform is extensively utilized by both multinational pharmaceutical and start-up biopharmaceutical companies. Melior has also established a high-quality, onshore, preclinical services capability, offering in vivo efficacy models in a broad range of therapeutic areas, pharmacokinetic evaluations, specialized animal models, and bioanalytical services to drug developers globally.
The company received a Venture - Series Unknown investment on 06 February 2013. Despite any disclosed information regarding the specific investors, this investment reflects the recognition and potential seen in Melior Discovery's innovative approach to identifying potential therapeutic indications and providing preclinical services to the pharmaceutical industry.
